BioMarin Pharmaceutical (NASDAQ:BMRN) Now Covered by Analysts at UBS Group

Research analysts at UBS Group began coverage on shares of BioMarin Pharmaceutical (NASDAQ:BMRN) in a research note issued to investors on Thursday. The brokerage set a “buy” rating and a $88.00 price target on the biotechnology company’s stock. UBS Group’s price objective would suggest a potential upside of 55.34% from the stock’s current price.

A number of other analysts have also commented on BMRN. Morgan Stanley boosted their price objective on BioMarin Pharmaceutical from $119.00 to $124.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Canaccord Genuity Group upped their price target on shares of BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. Raymond James Financial upgraded BioMarin Pharmaceutical from an “outperform” rating to a “strong-buy” rating and set a $109.00 price target for the company in a research note on Monday. Piper Sandler boosted their price objective on shares of BioMarin Pharmaceutical from $88.00 to $90.00 and gave the company an “overweight” rating in a report on Tuesday, September 1st. Finally, BMO Capital Markets reissued an “outperform” rating on shares of BioMarin Pharmaceutical in a research report on Wednesday, September 16th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $88.87.

BioMarin Pharmaceutical Trading Up 2.7%

BMRN traded up $1.51 during trading on Thursday, hitting $56.65. The company’s stock had a trading volume of 603,651 shares, compared to its average volume of 2,074,614. BioMarin Pharmaceutical has a twelve month low of $49.26 and a twelve month high of $70.98. The company has a quick ratio of 1.32, a current ratio of 2.39 and a debt-to-equity ratio of 0.56. The stock’s fifty day moving average price is $63.30 and its 200-day moving average price is $58.67. The firm has a market capitalization of $10.97 billion, a P/E ratio of 152.96, a PEG ratio of 0.37 and a beta of 0.22.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.95 by $0.25. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The company had revenue of $989.71 million for the quarter, compared to analysts’ expectations of $932.03 million. During the same quarter in the prior year, the firm earned $1.44 EPS. The business’s revenue was up 20.0% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Analysts anticipate that BioMarin Pharmaceutical will post 4.10 EPS for the current year.

Institutional Trading of BioMarin Pharmaceutical

Several institutional investors have recently made changes to their positions in the business. Primecap Management Co. CA purchased a new stake in BioMarin Pharmaceutical during the 2nd quarter valued at approximately $811,962,000. Caisse de depot et placement du Quebec purchased a new position in shares of BioMarin Pharmaceutical in the second quarter worth $70,749,000. Bank of New York Mellon Corp bought a new position in shares of BioMarin Pharmaceutical during the second quarter worth $66,107,000. River Road Asset Management LLC bought a new position in shares of BioMarin Pharmaceutical during the fourth quarter worth $53,865,000. Finally, Edmond DE Rothschild Holding S.A. purchased a new position in BioMarin Pharmaceutical during the second quarter valued at $39,312,000. Hedge funds and other institutional investors own 98.71% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company that develops and commercializes therapies for rare and serious genetic diseases. The company focuses on conditions with limited treatment options, using approaches that include enzyme replacement therapy, small-molecule medicines, biologics and gene therapy.

Its products include Vimizim for mucopolysaccharidosis type IV A, Naglazyme for mucopolysaccharidosis type VI, Brineura for CLN2 disease, Palynziq and Kuvan for phenylketonuria, and Voxzogo for children with achondroplasia and open growth plates.